Trials / Completed
CompletedNCT00603668
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.
Detailed description
Milatuzumab (hLL1, IMMU-115), a humanized anti-CD74 monoclonal antibody. Dose escalation will utilize 4 planned dose regimens with 4.0 or 8.0 mg/kg doses administered intravenously either twice weekly (days 1 and 4) or thrice weekly (days 1, 3 and 5) for 4 consecutive weeks. The four planned dose regimens will be labeled as dose level 1 to 4 corresponding to increasing levels of the total dose of milatuzumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | milatuzumab | two or three times a week dosing of hLL1 for a total of 4 weeks |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2013-01-01
- Completion
- 2013-02-01
- First posted
- 2008-01-29
- Last updated
- 2021-08-16
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00603668. Inclusion in this directory is not an endorsement.